A new study in the journal Blood shows that adding Mozobil (plerixafor) to Neupogen (filgrastim) prior to stem cell harvesting significantly increases harvest efficiency.

Mozobil is a new drug designed to mobilize stem cells from the bone marrow into the bloodstream, where they can be collected. Neupogen, which is commonly given prior to stem cell harvesting, stimulates the body to make white blood cells.

When given together, Mozobil and Neupogen have been shown to increase harvest efficiency in myeloma patients prior to autologous peripheral stem cell transplantation. The U.S. Food and Drug Administration …

Researchers from the Mayo Clinic today reported positive results of a Phase 2 clinical trial combining Actimid (pomalidomide) with low-dose dexamethasone (pom-dex) in relapsed or refractory multiple myeloma patients. The results were presented earlier today at the 50th annual meeting of the American Society of Hematology (ASH).

Actimid, also known as pomalidomide or CC-4047, is a molecular relative of the commonly used myeloma treatment thalidomide (Thalomid). Like thalidomide, Actimid is an immunomodulatory agent, meaning that it has the ability to alter or regulate the body's immune response. Both drugs …